`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`NALOX-1 PHARMACEUTICALS, LLC,
`Petitioner,
`
`v.
`
`OPIANT PHARMACEUTICALS, INC.,
`Patent Owner.
`__________________
`
`Case No. IPR2019-00694
`U.S. Patent No. 9,629,965
`__________________
`
`
`
`JOINT AMENDED MANDATORY NOTICES OF PATENT OWNERS
`ADAPT PHARMA OPERATIONS LIMITED AND
`OPIANT PHARMACEUTICALS, INC.
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owners Adapt Pharma Operations
`
`Limited (“Adapt”) and Opiant Pharmaceuticals, Inc. (“Opiant”) jointly submit the
`
`Case No. 2019-00694
`U.S. Patent No. 9,629,965
`
`following amended mandatory notices:
`
`I.
`
`Real Parties in Interest, 37 C.F.R. § 42.8(b)(1)
`
`Adapt and Opiant are the assignees of U.S. Patent Nos. 9,211,253;
`
`9,468,747; and 9,629,965.
`
`Adapt is a wholly owned subsidiary of Adapt Pharma Limited, which is a
`
`wholly owned subsidiary of Emergent Acquisition Limited. Emergent Acquisition
`
`Limited is a wholly owned subsidiary of Emergent International Inc., which is a
`
`wholly owned subsidiary of Emergent BioSolutions Inc. Emergent BioSolutions
`
`Inc. is a publicly held company, and no publicly held company owns 10% or more
`
`of Emergent BioSolutions Inc.’s stock.
`
`Opiant is a publicly held company, and no publicly held company owns 10%
`
`or more of Opiant’s stock.
`
`II. Related Matters, 37 C.F.R. § 42.8(b)(2)
`
`Petitioner Nalox-1 Pharmaceuticals, LLC (“Nalox-1”) has filed the
`
`following related petitions for inter partes review:
`
`U.S. Patent No.
`9,211,253
`9,211,253
`9,211,253
`9,468,747
`
`Case No.
`IPR2019-00685
`IPR2019-00686
`IPR2019-00687
`IPR2019-00688
`
`2
`
`
`
`Case No. 2019-00694
`U.S. Patent No. 9,629,965
`
`
`
`
`
`U.S. Patent No.
`9,468,747
`9,468,747
`9,561,177
`9,561,177
`9,561,177
`9,629,965
`9,629,965
`9,629,965
`9,775,838
`9,775,838
`9,775,838
`
`Case No.
`IPR2019-00689
`IPR2019-00690
`IPR2019-00691
`IPR2019-00692
`IPR2019-00693
`IPR2019-00694
`IPR2019-00695
`IPR2019-00696
`IPR2019-00697
`IPR2019-00698
`IPR2019-00699
`
`The Board has denied institution of Nalox-1’s petitions in Case Nos.
`
`IPR2019-00686, IPR2019-00687, IPR2019-00689, IPR2019-00690, IPR2019-
`
`00691, IPR2019-00692, IPR2019-00693, IPR2019-00695, IPR2019-00696,
`
`IPR2019-00697, IPR2019-00698, and IPR2019-00699.
`
`U.S. Patent No. 9,211,253; U.S. Patent No. 9,468,747; U.S. Patent No.
`
`9,561,177; U.S. Patent No. 9,629,965; and U.S. Patent No. 9,775,838 have been
`
`asserted in Adapt Pharma Operations Ltd., et al. v. Teva Pharmaceuticals USA,
`
`Inc., et al., Case 2:16-cv-07721-JLL-JAD (D.N.J.) (consolidated), filed October
`
`21, 2016; and Adapt Pharma Operations Ltd., et al. v. Perrigo UK FINCO Limited
`
`Partnership, Case 2:18-cv-15287-JLL-JAD (D.N.J.), filed October 25, 2018.
`
`Administrative matters that would be or could be affected by this proceeding
`
`include pending U.S. patent applications 16/551,524, and 16/595,631.
`
`3
`
`
`
`Case No. 2019-00694
`U.S. Patent No. 9,629,965
`
`III. Lead & Backup Counsel, 37 C.F.R. § 42.8(b)(3)
`
`Opiant has designated the following individual as lead counsel. See
`
`Mandatory Notices of Patent Owner Opiant Pharmaceuticals, Inc. (Paper No. 4).
`
`Robert F. Green
`Reg. No. 27,555
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue, Suite 3900
`Chicago, IL 60611
`rgreen@greengriffith.com
`
`Opiant has designated the following individual as first backup counsel. Id.
`
`Jessica Tyrus Mackay
`Reg. No. 64,742
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue, Suite 3900
`Chicago, IL 60611
`jmackay@greengriffith.com
`
`Adapt designates the following attorneys as backup counsel:
`
`Jessamyn S. Berniker
`Reg. No. 72,328
`Williams & Connolly LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`jberniker@wc.com
`
`Ana C. Reyes
`(Pro Hac Vice motion to be submitted)
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5000
`F: (202) 434-5029
`areyes@wc.com
`
`4
`
`
`
`
`
`Case No. 2019-00694
`U.S. Patent No. 9,629,965
`
`David M. Krinsky
`Reg. No. 72,339
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5000
`F: (202) 434-5029
`dkrinsky@wc.com
`
`Anthony H. Sheh
`Reg. No. 70,576
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5436
`F: (202) 434-5029
`asheh@wc.com
`
`Opiant designates the following attorney as backup counsel:
`
`Ann K. Kotze
`Reg. No. 76,570
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue, Suite 3900
`Chicago, IL 60611
`akotze@greengriffith.com
`
`Powers of attorney appointing these attorneys to transact all business in this
`
`proceeding on behalf of Adapt or Opiant, respectively, have been submitted or will
`
`be submitted with this amended mandatory notice information.
`
`5
`
`
`
`
`IV. Service Information, 37 C.F.R. § 42.8(b)(4)
`
`Counsel for Adapt and Opiant submit the following service information:
`
`Case No. 2019-00694
`U.S. Patent No. 9,629,965
`
`Electronic mail addresses:
`
`Postal mail addresses:
`
`Telephone numbers:
`
`Facsimile number:
`
`
`
`jberniker@wc.com, areyes@wc.com
`dkrinsky@wc.com,
`asheh@wc.com,
`EmergentNarcan@wc.com,
`rgreen@greengriffith.com,
`jmackay@greengriffith.com,
`akotze@greengriffith.com
`
`Jessamyn S. Berniker
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`
`Jessica Tyrus Mackay
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue
`Suite 3900
`Chicago, IL 60611
`
`(202) 434-5000, (313) 883-8000
`
`(202) 434-5029
`
`Counsel for Adapt consent to electronic service by email at
`
`jberniker@wc.com, areyes@wc.com, dkrinsky@wc.com, asheh@wc.com, and
`
`EmergentNarcan@wc.com.
`
`Counsel for Opiant consents to electronic service by email at
`
`rgreen@greengriffith.com, jmackay@greengriffith.com, and
`
`akotze@greengriffith.com
`
`6
`
`
`
`
`
`Date: November 19, 2019
`
`
`
`
`
`Case No. 2019-00694
`U.S. Patent No. 9,629,965
`
`Respectfully submitted,
`
`/Jessamyn S. Berniker/
`
`Jessamyn S. Berniker (Reg. No. 72,328)
`Ana C. Reyes (Pro Hac Vice motion to
`be submitted)
`David M. Krinsky (Reg. No. 72,339)
`Anthony H. Sheh (Reg. No. 70,576)
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5000
`F: (202) 434-5029
`jberniker@wc.com
`areyes@wc.com
`dkrinsky@wc.com
`asheh@wc.com
`
`Counsel for Patent Owner
`Adapt Pharma Operations Limited
`
`/Jessica Tyrus Mackay/
`Robert F. Green (Reg. No. 27,555)
`Jessica Tyrus Mackay (Reg. No. 64,742)
`Ann K. Kotze (Reg. No. 76,570)
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue
`Suite 3900
`Chicago, IL 60611
`(313) 883-8000
`jmackay@greengriffith.com
`
`Counsel for Patent Owner
`Opiant Pharmaceuticals, Inc.
`
`
`
`7
`
`
`
`Case No. 2019-00694
`U.S. Patent No. 9,629,965
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certifies that a true
`
`and correct copy of the foregoing was served on November 19, 2019, by delivering
`
`a copy via electronic mail on the following attorneys of record:
`
`Yelee Y. Kim
`Janine A. Carlan
`Richard Berman
`Bradford Frese
`Christopher Yaen
`ARENT FOX LLP
`1717 K Street NW
`Washington, DC 20036
`Yelee.Kim@arentfox.com
`Janine.Carlan@arentfox.com
`Richard.Berman@arentfox.com
`Bradford.Frese@arentfox.com
`Christopher.Yaen@arentfox.com
`
`
`
`
`
`
`Jessamyn S. Berniker
`Ana C. Reyes
`David M. Krinsky
`Anthony H. Sheh
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`jberniker@wc.com
`areyes@wc.com
`dkrinsky@wc.com
`asheh@wc.com
`EmergentNarcan@wc.com
`
`Robert F. Green
`Jessica Tyrus Mackay
`Ann K. Kotze
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue
`Suite 3900
`Chicago, IL 60611
`rgreen@greengriffith.com
`jmackay@greengriffith.com
`akotze@greengriffith.com
`
`/Jessica Tyrus Mackay/
`Jessica Tyrus Mackay
`Reg. No. 64,742
`
`
`
`
`
`
`8
`
`